Dear Valued Customers, Partners and Industry Colleagues,
Syneos Health shares its heartfelt empathy with the communities impacted worldwide by COVID-19. As the world responds to this pandemic, we remain committed to supporting you to ensure that the vital work of delivering new therapies to patients continues.
I’m writing to make you aware of the precautions we are taking to protect the health and safety of our employees and their families, our customers, patients and communities. I also want to assure you that we’re here to listen and be agile as we all work together to navigate this global health crisis. At the forefront is our commitment to help fight the pandemic by working with customers and partners pursuing innovative ways to get effective therapies to COVID-19 patients as quickly as possible.
Customer service, business continuity and virtual work
Syneos Health is making every effort to minimize the impact of this situation and ensure the timeliness and quality of the work we do.
More than 50% of our employees already work in a remote format and we have robust technologies in place to transition our other employees to efficiently and effectively provide virtual service. We’ve developed remote business-specific guidelines and tools to work in a fully adaptive style.
We are intensely focused on ensuring clinical trials proceed, and that site staff and patients are safe and in compliance with governmental policies. We have provided guidance for risk-based and remote monitoring in high-impact/restricted regions, and we have the ability to implement our remote monitoring strategy on a global scale as needed. Teams will be in direct contact with you to recommend the appropriate individual deployment strategy as needed. We’ve also been working in lockstep and cross-collaborating with the Association of Clinical Research Organizations (ACRO) to create a harmonized risk-based monitoring approach that is aligned with regulatory agencies.
Additionally, our Deployment Solutions field teams and employees who conduct medical facility and clinic visits are following customer and government protocols. Our employees who work and collaborate at customer sites have also been advised to consult on office protocols and remote business practices they need to follow.
Across our entire business, from our Clinical to Commercial operations, our teams are fully prepared to conduct all business-related engagements virtually while still supporting the important goal of delivering life-saving medicines.
Health and safety
The health and safety of our employees and their families, our customers, patients and our communities is our primary focus.
Health is who we are and embedded in everything we do. Our employees in APAC, Europe and North America who were not previously remote are now working virtually, and we are assessing remaining locations on a daily basis. Our remote work protocols reinforce WHO and CDC guidelines to help prevent the spread of respiratory disease and support the practice of social distancing. We are advising employees who feel unwell to follow guidelines from their local ities for testing and treatment. We are also following strict quarantine rules in alignment with the most up-to-date government guidance for colleagues who may have been exposed to someone diagnosed with COVID-19. Additionally, we have instituted supplemental cleaning protocols in our offices during this period.
Global and non-essential domestic travel
All non-business critical travel has been restricted – virtually enabled platforms will bridge our communities.
With evolving travel restrictions, our leaders are following all governmental restrictions and evaluating all other meetings to make prudent decisions on how to optimize virtual connections. Our technology-empowered teams are continuing to meet business challenges and bring expertise to deliver against our shared objectives.
We recognize this unprecedented challenge will facilitate new ways of working and collaborating. On behalf of Syneos Health and our portfolio of businesses, we value our relationship with you, the shared impact we can make for patients, and we are committed to staying connected and supportive through this uncharted territory.
Should you have specific questions, please reach out to your Syneos Health business contact or via our regularly updated website.
If there are significant changes to the approach we have taken, we will inform you as appropriate.
Stay safe and be good,
Chief Executive Officer, Syneos Health
Chair, Association of Clinical Research Organizations (ACRO)
About Syneos Health
Syneos Health (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Our Company brings together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries, including a collective of businesses such as Addison Whitney, Adheris Health, Biosector 2, Cadent Medical Communications, Chandler Chicco Agency and GSW that speed our customers’ delivery of important therapies to patients.